Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine.
Treatment of palatal Kaposi's sarcoma (KS) with intralesional injection of vinblastine was seen to provide effective palliation. Of the ten patients studied, four had a 25% to 50% response, two 50% to 75% response, and four had 75% to 100% response with one or two intralesional injections of vinblastine. Response to treatment was followed for a mean of 3.6 months, with recurrence of lesions in two of ten patients.
Epstein
J B
JB
Cancer Control Agency of British Columbia, Vancouver, Canada.
Lozada-Nur
F
F
McLeod
W A
WA
Spinelli
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010157:Palatal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use*
D014747:Vinblastine